Lumos Pharma, Inc.

NasdaqGM:LUMO Stock Report

Market Cap: US$22.8m

Lumos Pharma Management

Management criteria checks 3/4

Lumos Pharma's CEO is Rick Hawkins, appointed in Jan 2011, has a tenure of 13.25 years. total yearly compensation is $952.87K, comprised of 61.1% salary and 38.9% bonuses, including company stock and options. directly owns 9.2% of the company’s shares, worth $2.10M. The average tenure of the management team and the board of directors is 4.1 years and 8.1 years respectively.

Key information

Rick Hawkins

Chief executive officer

US$952.9k

Total compensation

CEO salary percentage61.1%
CEO tenure13.3yrs
CEO ownership9.2%
Management average tenure4.1yrs
Board average tenure8.1yrs

Recent management updates

Recent updates

We're Keeping An Eye On Lumos Pharma's (NASDAQ:LUMO) Cash Burn Rate

Aug 25
We're Keeping An Eye On Lumos Pharma's (NASDAQ:LUMO) Cash Burn Rate

Is Lumos Pharma (NASDAQ:LUMO) In A Good Position To Deliver On Growth Plans?

Mar 13
Is Lumos Pharma (NASDAQ:LUMO) In A Good Position To Deliver On Growth Plans?

Lumos Pharma announces new buyback program

Aug 16

Here's Why We're Not Too Worried About Lumos Pharma's (NASDAQ:LUMO) Cash Burn Situation

Mar 22
Here's Why We're Not Too Worried About Lumos Pharma's (NASDAQ:LUMO) Cash Burn Situation

Companies Like Lumos Pharma (NASDAQ:LUMO) Are In A Position To Invest In Growth

Nov 04
Companies Like Lumos Pharma (NASDAQ:LUMO) Are In A Position To Invest In Growth

What Kind Of Investors Own Most Of Lumos Pharma, Inc. (NASDAQ:LUMO)?

Dec 09
What Kind Of Investors Own Most Of Lumos Pharma, Inc. (NASDAQ:LUMO)?

Lumos Pharma (LUMO) Investor Presentation - Slideshow

Nov 17

Lumos Pharma, Inc. 2020 Q3 - Results - Earnings Call Presentation

Nov 11

CEO Compensation Analysis

How has Rick Hawkins's remuneration changed compared to Lumos Pharma's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2023US$953kUS$583k

-US$34m

Sep 30 2023n/an/a

-US$33m

Jun 30 2023n/an/a

-US$32m

Mar 31 2023n/an/a

-US$31m

Dec 31 2022US$1mUS$582k

-US$31m

Sep 30 2022n/an/a

-US$28m

Jun 30 2022n/an/a

-US$29m

Mar 31 2022n/an/a

-US$30m

Dec 31 2021US$1mUS$571k

-US$30m

Sep 30 2021n/an/a

-US$27m

Jun 30 2021n/an/a

-US$18m

Mar 31 2021n/an/a

-US$15m

Dec 31 2020US$2mUS$516k

-US$6m

Compensation vs Market: Rick's total compensation ($USD952.87K) is above average for companies of similar size in the US market ($USD674.64K).

Compensation vs Earnings: Rick's compensation has been consistent with company performance over the past year.

CEO

Rick Hawkins (74 yo)

13.3yrs

Tenure

US$952,869

Compensation

Mr. Richard J. Hawkins, also known as Rick, is Operating Partner of Havencrest Healthcare Partners. He is the Founder of Lumos Pharma, Inc. and has been its Chairman of the Board since March 26, 2020, its...

Leadership Team

NamePositionTenureCompensationOwnership
Richard Hawkins
Founder13.3yrsUS$952.87k9.2%
$ 2.1m
John McKew
Chief Scientific Officer & President8yrsUS$904.79k0.032%
$ 7.4k
Lori Lawley
CFO & Principal Accounting Officer4.1yrsUS$569.78k0.10%
$ 23.0k
Lisa Miller
Senior Director of Investor Relationsno datano datano data
Bradley Powers
Chief Compliance Officer & General Counsel8.7yrsUS$853.06k0.050%
$ 11.5k
Aaron Schuchart
Chief Business Officer3.9yrsno data0.052%
$ 12.0k
Pisit Pitukcheewanont
Chief Medical Officerless than a yearno data0.031%
$ 7.0k
Eddie Varnado
Corporate Controller3yrsno datano data

4.1yrs

Average Tenure

57yo

Average Age

Experienced Management: LUMO's management team is considered experienced (4.1 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Richard Hawkins
Founder13.3yrsUS$952.87k9.2%
$ 2.1m
Lota Zoth
Independent Director11.4yrsUS$69.33k0.027%
$ 6.1k
Joseph S. McCracken
Independent Director4.1yrsUS$56.33k0.19%
$ 44.2k
Kevin Lalande
Independent Director10.2yrsUS$54.33k0.013%
$ 3.0k
Thomas Raffin
Lead Independent Director25.3yrsUS$86.83k0.12%
$ 26.4k
George Werther
Member of Scientific Advisory Boardno datano datano data
Chad Johnson
Independent Director6.1yrsUS$64.33k0.013%
$ 3.0k
An van Es-Johansson
Independent Director3.2yrsUS$52.83k0.011%
$ 2.4k
Ron Rosenfeld
Member of Scientific Advisory Boardno datano datano data
Peter Clayton
Member of Scientific Advisory Boardno datano datano data
Reiko Horikawa
Member of Scientific Advisory Boardno datano datano data
Mark Bach
Scientific Advisory Board Member2.8yrsno datano data

8.1yrs

Average Tenure

64.5yo

Average Age

Experienced Board: LUMO's board of directors are considered experienced (8.1 years average tenure).

Simply Wall St™
Simply Wall Street Pty Ltd
Level 7, 320 Pitt Street, Sydney
Download on the App StoreGet it on Google Play
Popular Markets
USAUUKINCAZA
About UsCareersPlansLogin
Help CenterLatest CoveragePodcastsAffiliate ProgramBusiness & Enterprise
Financial Services GuideTerms and ConditionsPrivacy PolicyLogos provided by Clearbit
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.